Genprex, Inc. (GNPX)
| Market Cap | 147.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.94M |
| Shares Out | 35.52M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 20 |
| Last Price | $3.40 |
| Previous Close | $3.82 |
| Change ($) | -0.42 |
| Change (%) | -10.99% |
| Day's Open | 3.86 |
| Day's Range | 3.22 - 3.92 |
| Day's Volume | 1,979,440 |
| 52-Week Range | 1.95 - 7.72 |
Genprex Inc (NASDAQ:GNPX) said its collaborators have presented positive preclinical data for the combination of REQORSA, the company's proprietary TUSC2 immunogene therapy, in combination with chemothe...
10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX) presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therape...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex collaborators report new, positive preclinical data for its lead drug candidate, REQORSA, at the 2021 AACR Annual Meeting.
Focused on developing life-changing therapies for patients with cancer and diabetes Advancing lead product REQORSA immunogene therapy for non-small cell lung cancer Struck licensing agreement with the ...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex' EVP and Chief Operating Officer will present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean
Genprex Inc (NASDAQ:GNPX) said Tuesday that preclinical data for its lead drug candidate REQORSA, its proprietary TUSC2 immunogene therapy, in non-small cell lung cancer (NSLC), will be featured in two ...
AUSTIN, Texas--(BUSINESS WIRE)--Preclinical Data for Genprex' TUSC2 Immunogene Therapy Will Be Featured in Two Presentations at the 2021 AACR Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's President and CEO will present at the Virtual Oncology Investor Conference on March 29
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at upcoming investor conferences in March 2021.
Genprex, Inc. (NASDAQ:GNPX) said it has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stoc...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
Genprex Inc (NASDAQ:GNPX) announced Monday the formation of a Clinical Advisory Board (CAB) to support its oncology and diabetes development programs. Comprised of preeminent clinical specialists, the ...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex forms a Clinical Advisory Board.
AUSTIN, Texas--(BUSINESS WIRE)--Genprex honors World Cancer Day.
AUSTIN, Texas--(BUSINESS WIRE)--Genprex issues January 2021 shareholder letter.
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present on February 4 at the Virtual Investor Conference.
This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at the MoneyShow Virtual Conference on January 28.
AUSTIN, Texas--(BUSINESS WIRE)--Genprex CEO will present at NobleCon on January 19 at 3:45 pm ET
AUSTIN, Texas--(BUSINESS WIRE)--Genprex Successfully Completes Manufacturing for REQORSA and Passes All Testing
The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opport...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces $12 million registered direct closing.
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Nasdaq: GNPX) (“Genprex” or the “Company”), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer an...
Genprex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. According to data from the World Health Organization, cancer is currently the second l...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex completes clinical-grade manufacturing of lead drug candidate, REQORSA
Genprex (GNPX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
AUSTIN, Texas--(BUSINESS WIRE)--Genprex completes major manufacturing milestone with completion of technology transfer
AUSTIN, Texas--(BUSINESS WIRE)--Genprex commences clinical trial site recruitment for Acclaim-1 clinical trial
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's COO will present on December 1 at the Diamond Equity Research Emerging Growth Invitational
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's Thomas Gallagher will participate as a panelist at the NYC-based Life Sciences Summit
AUSTIN, Texas--(BUSINESS WIRE)--George Gittes, MD Joins Genprex's Scientific Advisory Board
AUSTIN, Texas--(BUSINESS WIRE)--Genprex announces new clinical trial branding for upcoming trials in non-small cell lung cancer
AUSTIN, Texas--(BUSINESS WIRE)--Genprex receives conditional FDA acceptance of proprietary name Reqorsa(TM) for lead drug candidate
AUSTIN, Texas--(BUSINESS WIRE)--Genprex appoints Eric Chapdelaine to VP of Manufacturing
AUSTIN, Texas--(BUSINESS WIRE)--Genprex will present at the Zooming with LD Micro virtual event
AUSTIN, Texas--(BUSINESS WIRE)--Genprex will present at the Cell and Gene Meeting on the Mesa
AUSTIN, Texas--(BUSINESS WIRE)--Genprex appoints new Vice President of Regulatory Affairs
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's Chairman and CEO will present on September 1, 2020 at the LD 500 Virtual Conference
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will Present at the Proactive Investor Forum on August 4 at 1:40 p.m. ET
AUSTIN, Texas--(BUSINESS WIRE)--Genprex appears live on the Big Biz Show for a second time
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's collaborators at the University of Pittsburgh receive $2.5 million grant from the NIH to fund diabetes gene therapy study.
Shares of the micro-cap gene therapy company Genprex Inc (NASDAQ: GNPX) were advancing strongly on above-average volume Tuesday.
Shares of Genprex Inc. GNPX, +56.61% climbed 53% in morning trading on Wednesday after the company said the Food and Drug Administration had granted its experimental cancer treatment a fast-track design...
Shares of thinly-traded gene therapy company Genprex Inc (NASDAQ: GNPX) are soaring on more than 50 times their average volume Tuesday.
When companies see their shares rise by 100% or more in a single day, it’s usually because of a buyout or an extremely positive change in a company’s future prospects.
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Gene Therapies with Potential to Co...
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial n...
NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled “Gene Therapy Treatments Offer Hope f...
NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial ...
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of an audio press release broadcast titled, “Record Revenues, Milestone Achieve...
About GNPX
Genprex, Inc. operates as a clinical-stage gene therapy company that develops treatments for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new treatment options for patient populations with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle... [Read more...]
| Industry Biotechnology | IPO Date Mar 29, 2018 |
| CEO J. Rodney Varner | Employees 12 |
| Stock Exchange NASDAQ | Ticker Symbol GNPX |
Analyst Forecasts
According to one analyst, the rating for Genprex stock is "Strong Buy" and the 12-month stock price forecast is 6.67.